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Abstract: The imaging of drugs inside tissues is pivotal in oncology to assess whether a drug
reaches all cells in an adequate enough concentration to eradicate the tumor. Matrix-Assisted Laser
Desorption Ionization Mass Spectrometry Imaging (MALDI-MSI) is one of the most promising
imaging techniques that enables the simultaneous visualization of multiple compounds inside tissues.
The choice of a suitable matrix constitutes a critical aspect during the development of a MALDI-MSI
protocol since the matrix ionization efficiency changes depending on the analyte structure and its
physico-chemical properties. The objective of this study is the improvement of the MALDI-MSI
technique in the field of pharmacology; developing specifically designed nanostructured surfaces
that allow the imaging of different drugs with high sensitivity and reproducibility. Among several
nanomaterials, we tested the behavior of gold and titanium nanoparticles, and halloysites and carbon
nanotubes as possible matrices. All nanomaterials were firstly screened by co-spotting them with
drugs on a MALDI plate, evaluating the drug signal intensity and the signal-to-noise ratio. The best
performing matrices were tested on control tumor slices, and were spotted with drugs to check the
ion suppression effect of the biological matrix. Finally; the best nanomaterials were employed in a
preliminary drug distribution study inside tumors from treated mice.
Keywords: mass spectrometry imaging; MALDI; TiO2; gold nanoparticles; halloysite; cancer imaging
1. Introduction
In drug discovery and development it is important to understand the pharmacokinetics,
investigating the absorption, distribution, metabolism, and excretion (ADME) of molecules.
Several analytical methods, based on high-performance liquid chromatography (HPLC) and Liquid
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chromatography tandem-mass spectrometry (LC-MS/MS), have been developed and employed
on plasma and tissue homogenates to establish drug concentration profiles of drugs [1]. Classical
pharmacokinetic studies measure the average drug accumulation in tissues assuming a homogeneous
distribution of the molecule and ignore organ compartmentalization. However, the manner in which a
compound and its metabolites localize and distribute inside a tissue is important in order to ascertain
whether they reach the intended target site. This is particularly true in oncology where the data
obtained may reveal very little about the drug’s ability to penetrate the tumor, because they neglect
the information about the structure of the tumor microenvironment resulting in a loss of information
about spatial distribution [2,3]. In particular, the imaging of drugs inside biological tissues is pivotal
in oncology to assess whether a drug reaches high enough concentrations in all tumor cells and to
develop new strategies to improve penetration and the outcome of chemotherapy [4].
In recent decades, several imaging techniques have been developed to investigate the distribution
of compounds inside a tissue, such as magnetic resonance imaging (MRI), positron emission
tomography (PET), or wall body autoradiography (WBA), and are routinely used in clinical
diagnosis [5–10].
Mass spectrometry imaging (MSI) is one of the latest, rapidly growing surface analysis techniques
for the detection, localization, and identification of molecules in tissues [11–13]. MSI permits the
simultaneous visualization of multiple endogenous or exogenous compounds with high specificity
and sensitivity, without the need for radiolabeled compounds [14,15]. It was developed in the late
1970s with the development of laser microprobe mass spectrometry (LMMS) and laser microprobe
mass analysis (LAMMA) [16]. These techniques use a focused laser beam that generates a light pulse
to desorb and ionize molecules inside solid samples. Ionized molecules are excited and accelerated
into a time of flight (TOF) mass analyzer, particularly suitable for the imaging of small molecules
(MW < 10,000 Da). Laser desorption/ionization based techniques have always been the most widely
used in mass spectrometry for imaging [17] and they were soon implemented with the introduction
of organic matrices to improve the detection of higher mass species, leading to the development of
Matrix Assisted Laser Desorption Ionization (MALDI).
MALDI is the prevailing MSI technique used in pre-clinical and clinical research [11,18] to obtain
information about biomolecules over a wide mass range, in living cells and tissues [19]. Originally
developed for the imaging of molecules with high molecular weights like proteins and peptides [20,21],
it is now also used to visualize the distribution of small molecules (MW < 1000 Da) like drugs and
metabolites as well [14,22–25].
The principle behind MALDI-MSI is to acquire a mass spectrum for each point of a tissue section
by rastering a laser beam at defined geometrical coordinates. The UV laser energy is absorbed by
a matrix present in a homogeneous layer on the tissue slice that facilitates analyte extraction in the
MALDI ion source [26,27]. The choice of the suitable matrix for the molecule of interest is primarily
driven by empirical results and is critical during the development of a MALDI-MSI protocol, since
matrix ionization efficiency can change depending on the analyte structure and its physicochemical
properties. Typically used matrices for MALDI experiments (organic compounds such as sinapinic acid,
2,5-dihydroxybenzoic acid, or a-cyano-4-hydroxycinnamic acid) are inadequate for small molecule
imaging because of their excessive fragmentation and high background noise in the low mass region
that can mask the analyte ion signal, and also because of their co-crystallization with the analyte that
can affect the spatial resolution [14]. For these reasons the study of MALDI matrices is continuously in
progress and recently, besides the advances in nanotechnologies, several new compounds have been
tested as possible matrices to enhance desorption/ionization [28].
A different approach based on the use of inorganic fine particles takes advantage of their
physicochemical properties such as high photo-adsorption, low heat capacity, and large surface area.
This ensures rapid heating and highly localized and uniform energy deposition, resulting in efficient
sample desorption and ionization [29], allowing for the detection of large intact molecules. The great
advantage of the use of nanoparticles as MALDI matrices is the almost complete absence of background
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signals from matrix degradation that made them suitable for small molecule imaging studies. Another
positive aspect is that the spatial resolution only depends on the instrumental specifications such as
laser spot diameter and not on the matrix crystal dimensions [14]. Among several nanomaterials, we
tested gold and titanium nanoparticles, and halloysites and carbon nanotubes as possible inorganic
MALDI matrices.
The use of gold and platinum nanostructures in laser desorption/ionization (LDI) MS of low
molecular weight compounds was reviewed by Bergman et al. [30]. Gold nanoparticles (AuNPs) have
received attention for their suitability in surface assisted laser desorption ionization mass spectrometry
(SALDI-MS), where these inorganic substrates offer large surface areas, simple sample preparation
techniques, flexibility, and selectivity of sample deposition [31].
Titanium dioxide can be considered as a matrix for MALDI, since the laser wavelength falls in
the range of its absorption band. In particular, the literature reports some examples of the use of this
material for the determination of carbohydrates [32] and antitumor drugs [22,33].
Halloysite (HNT), a naturally occurring aluminosilicate nanotube (Al2Si2O5(OH)4·2H2O), is a
two-layered aluminosilicate, with a predominantly hollow tubular structure. Chemically, the outer
surface of the HNTs has properties similar to SiO2, while the inner cylinder core is related to Al2O3.
In a recent paper, halloysite nanoclay showed good potential as a SALDI surface for the rapid analysis
of low molecular mass polyesters and their degradation products [34].
Carbon nanotubes (CNTs) are allotropes of carbon with a cylindrical nanostructure. They have
been reported to be an effective MALDI matrix for small molecules [35], eliminating the interfering
matrix peaks and forming a web morphology to fully disperse the analyte and allow for strong
ultraviolet absorption for enhanced pulsed laser desorption and ionization.
We compared the ability of these five nanostructured matrices to ionize six different anticancer
drugs: taxans (paclitaxel, PTX and ortataxel, OTX), tyrosine kinase inhibitors (imatinib, IMT and
lucitanib, LCT), an antineoplastic antibiotic (doxorubicin, DOXO), and a DNA binding protein
(trabectedin, ET) [36,37]. All nanomaterials were firstly screened to compare their ionization
efficiency by co-spotting them with equimolar concentrations of the drugs directly on the MALDI
plate. We therefore evaluated the drug signal intensity, expressed as the signal to-noise ratio (S/N),
considering both the matrix degradation effects that lead to excessive background chemical noise and
the instrumental contamination that prevents the effective use of nanomaterials. The best performing
matrices were tested on control tumor slices spotted with drugs, to assess the influence of the biological
matrix on the intensity of the analytes’ ion signal. Finally, the best nanomaterials were applied in a
preliminary drug distribution study inside tumors harvested from treated mice.
The main objective of this study is the improvement of the MALDI-MSI technique in the field of
pharmacology, developing specifically designed surfaces for the imaging of different anticancer drugs,
with high spatial resolution, sensitivity, and reproducibility.
2. Results
All nanostructured materials were deeply characterized by the morphological, structural, and
surface points of view, by ultraviolet-visible spectroscopy (UV), transmission electron microscope
(TEM), scanning electron microscope (SEM), and dynamic light scattering (DLS) analyses. Relevant
features are reported in Table 1. Figure 1 shows TEM images of the nanoparticles.
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Table 1. Physico-chemical characteristics of all tested nanomaterials.
dTEM/nm SBET/(m2·g−1) Vpores/(mL·g−1)
Au nanoparticles 20 ± 2 n.d. n.d.
TiO2 HOMBIKAT
nanoparticles 7 ± 2 350 0.26
TiO2 P25 nanoparticles 24 ± 6 52 0.27
Halloysite
Average diameter: 30–70
Inner lumen diameter: 15
Average Length: 500–2000
65 * 1.25 *
Carbon nanotubes * Average diameter: 9.5Average Length: 1500 250–300 n.a.
Notes: n.d. not determinable; n.a. not available; * from technical data sheets.Nanomaterials 2017, 7, 71 4 of 19 
 
 
Figure 1. Transmission electron microscope (TEM) images of (a) Au nanoparticles (AuNPs); (b) 
Halloysite nanotubes (HNTs); (c) TiO2 P25 nanoparticles; (d) TiO2 Hombikat nanoparticles UV100 and 
(e) Carbon nanotubes (CNTs) at different magnifications (scale bars correspond to 20 nm and 5 nm). 
All nanostructured matrices were firstly screened by co-spotting them with equimolar 
concentrations of six anticancer drugs on the MALDI plate and evaluating both the signal intensity 
and the S/N for each combination of drug and matrix. The detected MS fragments for each drug are 
reported in Figures A1–A6. 
Almost all drugs were successfully ionized both in negative and positive ion modes using gold, 
halloysite, and titanium, while trabectedin (ET) was detectable only in positive ion mode at m/z 743 
after losing a water molecule (Figure 2). P25 and Hombikat TiO2 nanoparticles were particularly 
suitable to visualize the two taxans, PTX (m/z 284) and OTX (m/z 271) in negative ion mode, but they 
also allowed the ionization of smaller molecules like IMT (m/z 492) and LCT (m/z 373). AuNPs gave 
more intense signals, especially in positive ion mode for the tyrosine-kinase inhibitor IMT as a 
sodium adduct at m/z 515. Compared to TiO2 nanoparticles, AuNPs were more efficient for ionizing 
and visualizing smaller molecules such as IMT and LCT, giving a more intense signal in general. 
HNTs gave good visualization only for three of the six drugs: PTX, IMT, and LCT. CNTs efficiently 
ionized all drugs both in negative and positive ion modes, but could not be used for imaging. 
Figure 1. Transmission electron microscope (TEM) images of (a) Au nanoparticles (AuNPs);
(b) Halloysite nanotubes (HNTs); (c) TiO2 P25 nanoparticles; (d) TiO2 Hombikat nanoparticles UV100
and (e) Carbon nanotubes (CNTs) at different magnifications (scale bars correspond to 20 nm and
5 nm).
All nanostructured matrices were firstly screened by co-spotting them with equimolar
concentrations of six anticancer drugs on the MALDI plate and evaluating both the signal intensity
and the S/N for each combination of drug and matrix. The detected MS fragments for each drug are
reported in Figures A1–A6.
Almost all dr gs wer successfully ionized both in negative and positive ion modes using gold,
halloysite, and titanium, while trabectedin (ET) was detectable only in positive ion mode at m/z 743
after losing a water molecule (Figure 2). P25 and Hombikat TiO2 nanoparticles were particularly
suitable to visualize the two taxans, PTX (m/z 284) and OTX (m/z 271) in negative ion mode, but they
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also allowed the ionization of smaller molecules like IMT (m/z 492) and LCT (m/z 373). AuNPs gave
more intense signals, especially in positive ion mode for the tyrosine-kinase inhibitor IMT as a sodium
adduct at m/z 515. Compared to TiO2 nanoparticles, AuNPs were more efficient for ionizing and
visualizing smaller molecules such as IMT and LCT, giving a more intense signal in general. HNTs
gave good visualization only for three of the six drugs: PTX, IMT, and LCT. CNTs efficiently ionized
all drugs both in negative and positive ion modes, but could not be used for imaging.Nanomaterials 2017, 7, 71 5 of 19 
 
 
Figure 2. Drug standards (100 pmol/µL) spotted on the matrix-sssisted laser desorption/ionization 
MALDI plate with different nanostructured materials. For each drug, the acquisition in negative ion 
mode is shown on the left and the acquisition in positive ion mode is shown on the right of each 
column. The negative ion mode gives more intense signals for almost all drugs except for trabectedin 
(ET), which was detectable only in positive ion mode. 
Figure 3 shows, as an example, the mass spectrum of 50 pmol of PTX which in negative ion mode 
with CNTs fragments to produce ions at m/z 284 as a base peak. In this mass region the spectrum has 
a very high S/N, suggesting a good effectiveness of the technique with this kind of matrix. 
Unfortunately, CNTs tended to fly off from the target plate when subjected to the laser pulse, 
contaminating the ion source and interfering with the instrument functionality. 
 
Figure 3. MALDI mass spectrum of paclitaxel (PTX, 50 pmol) in negative ion mode using CNTs. The 
fragment ion m/z 284 is clearly observable in the spectrum with a high S/N ratio. 
The different performances of the nanomaterials towards the ionization of the drug molecules 
may be ascribed to many factors, starting with the physico-chemical properties (Table 1), their ability 
of energy sorption from the laser source, and transfer to the analytes. Figure 4a shows the diffuse 
Figure 2. Drug standards (100 pmol/µL) spotted on the matrix-sssisted laser desorption/ionization
MALDI plate with different nanostructured materials. For each drug, the acquisition in negative ion
mode is shown on the left and the acquisition in positive ion mode is shown on the right of each
column. The negative ion mode gives more intense signals for almost all drugs except for trabectedin
(ET), which was detectable only in positive ion mode.
Figure 3 shows, as an example, the mass spectrum of 50 pmol of PTX which in negative ion mode
with CNTs f agm nts to produc ions at m/z 284 as a base eak. In this mass region the spectrum has a
very high S/N, sug esting a good effectiveness of t e techniqu with his k nd of matrix. Unfortunately,
CNTs tended to fly off from the target plate when subjected to the laser pulse, contaminating the ion
source and interfering with the instrument functionality.
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The different performances of the nanomaterials towards the ionization of the drug molecules
may be ascribed to many factors, starting with the physico-chemical properties (Table 1), their ability
of energy sorption from the laser source, and transfer to the analytes. Figure 4a shows the diffuse
reflectance spectra (DRS) of the tested solid nanomaterials and Figure 4b shows the absorption spectra
of the AuNP slurry. Non-conducting HNTs presented no absorption peak in the explored UV-Vis
range, particularly in the laser emission wavelengths (grey shadow in Figure 4). This resulted in a
poor performance of these materials in visualizing the drug fragments.
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Figure 4. UV-Vis absorption behavior of the adopted nanostructured materials. The grey shadow
represents the laser emission wavelengths. (a) Diffuse reflectance spectra (DRS) of halloysite and
titanium nanomaterials; (b) Absorption spectra of AuNP slurry.
Both titanium samples, instead, showed a strong absorption (inflection point of the curves)
particularly in the laser emis ion range. However, not all the absorbed energy could be tra sferred to
the target molecules, as these materials are semiconductors. This yields a good compromise between
the absorbed and released energy, with promising results in ionizing almost all the bigger drug
molecules. Unfortunately, the released energy is still so high that the small fragments are not detected
because of their complete mineralization (no signals are detectable in the low MS region, m/z < 100).
The best performing material seems to be the AuNPs. The UV-Vis relative absorption lies
far from the laser absorption and there is only a small shoulder in the desired ra ge (Figure 4b).
The partial energy absorption is enough to ionize both the large and the small molecules (as it is a
conductive material), but not sufficient to completely destroy them. However, by considering the same
nanomaterial matrix, different ionization results are obtained by varying the chemical nature of the
analyte, and thus their interaction/adsorption onto the solid support. Further studies are required to
show which material is the best one for the target molecule.
Based on the present findings, the most promising nanomaterials (P25 TiO2, Hombikat TiO2,
and particularly AuNPs) were tested to assess how the biological matrix influenced the intensity of
the analyte ion signal and for interfering signals by spotting drug standards on control tumor tissue
slices that were then sprayed with each matrix for imaging experiments (Figure 5). The results on
the tissues confirm the previous screening on the plates: TiO2 P25 nanoparticles allowed desorption
and ionization mainly for PTX (m/z 284) and OTX (m/z 260) in negative ion mode; TiO2 Hombikat
efficiently ionized the two taxans PTX and OTX in negative ion mode but also IMT and OTX in
positive ion mode. AuNPs efficiently visualized almost all drugs (especially PTX and IMT) spotted on
tissue (Figure 5c), but gave a low S/N ratio in positive ion mode. Finally, the HNTs matrix caused
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strong signal suppression when sprayed on tissues with the airbrush and was therefore excluded from
further experiments.
Based on the results obtained from the control tissues spotted with the drug standards, TiO2
and AuNPs were selected to study the drug distribution inside tumors harvested from mice bearing
xenografts treated with a single dose of drugs (60 mg/kg intravenously (i.v.) for PTX, 400 mg/kg
per os (p.o.) for IMT, 20 mg/kg p.o. for LCT). Figure 6 shows that TiO2 based matrices appear to be
suitable for visualizing the PTX distribution inside treated tissues in negative ion mode with high
sensitivity, but did not give good visualization of IMT in negative or positive ion mode. In contrast,
the nanogold-based matrix allowed a better visualization of the IMT distribution, highlighting its
peripheral localization inside treated mesothelioma (even though there is high background noise).
Both TiO2 and gold nanoparticles were not suitable for LCT distribution studies inside treated tumors.
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3. Discussion
The imaging of drugs inside biological tissues is pivotal in oncology to understand how a
compound and its metabolites are localized and distributed inside a tissue, in order to check that they
reach the intended target site. Therefore, there is a growing need for methods to assess whether a
drug reaches all tumor cells in adequate concentrations and to develop new strategies to improve
penetration and the outcome of chemotherapy [38]. In this field, MSI is acquiring an important role
thanks to its superior specificity and sensitivity [39]. However, a major shortcoming in setting up a
MALDI-MSI method is the choice of a suitable matrix to guarantee efficient and reproducible ionization
with low background noise. To address this problem, we screened different nanomaterials for the
imaging of small molecules in biological tissues. Nanoparticles were suitable as MALDI matrices for
small molecule imaging because of their uniform deposition over tissues (increasing lateral resolution)
and the lack of background signals from matrix degradation. TiO2 nanoparticles have been previously
reported to be suitable for MALDI mass spectrometry analysis of low molecular weight compounds,
with almost complete absence of background noise [40], and recently gold based nanoparticles have
been reported to assist laser desorption/ionization, avoiding co-crystallization of the analyte and
the matrix [41,42]. For the synthesis of AuNPs, we used a classical chemical reduction method that
has been extensively used in the preparation of nanoparticles because this method is simple, cheap,
and can be used to prepare large quantities of nanoparticles with an accurate shape and dimensions.
Among the conventional methods of synthesis of AuNPs by reduction of gold (III) derivatives, the
most popular is that using citrate reduction of HAuCl4 in water, which was introduced by Turkevitch
and revisited by Kimling [43,44].
We tested common nanoparticles with different features with six types of drugs, currently used as
anticancer drugs in clinical settings. While the carbon nanotubes based matrix has been reported to
provide higher detection sensitivity than classical organic matrices [35], and it enhanced the ionization
of certain analytes of our interest, it was excluded from MSI applicability because of the marked
instrumental contamination.
PTX efficiently ionizes with titanium based matrices which were however less suitable for the
ionization of a smaller molecule such as IMT. AuNPs were convenient for the ionization and for the
imaging of IMT, enlarging our ability to visualize different kind of molecules.
These results confirm that there is not a single type of matrix that suits all drugs. Further studies
are needed to clarify the interactions between matrix and analyte to define case-by-case how to choose
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the best matrix and the best fitting combination that gives high sensitivity and therefore a good
detection of drug distribution in the imaging of molecules inside biological tissues.
Further studies are also needed to accurately understand the mechanism of interaction between
the matrix and analyte. Determining out why a particular matrix is more appropriate for the imaging
of a certain drug could give clues for developing of new nanomaterials with designed texture for the
imaging of a larger group of small molecules, to investigate drug distribution in primary tumors or
metastases, while also offering new opportunities for the visualization of endogenous molecules.
4. Experimental Section
4.1. Drugs and Reagents
Paclitaxel (PTX, Indena S.p.A, Milan, Italy), ortataxel (OTX, Indena S.p.A, Milan, Italy), and
imatinib (IMT, Norvartis, Basel, Switzerland) were dissolved in 50% ethanol, trabectedin (ET,
PharmaMar Colmenar Viejo, Madrid, Spain) and lucitanib (LCT, Servier, Neully-sur-Seine, France)
were dissolved in 50% methanol, and doxorubicin (DOXO, Nerviano Medical Science, Milan, Italy)
was dissolved in H2O, all at a concentration of 100 pmol/µL.
For mouse treatments, PTX was dissolved in 50% Cremophor EL (Sigma Aldrich, Saint Louis,
MO, USA) and 50% ethanol and further diluted in saline immediately before use. IMT and LCT were
suspended in 0.5% Methocel.
4.2. Adopted Nanomaterials
Gold nanoparticles (AuNPs) of 20 nm diameter were synthesized as follows: an aqueous solution
of HAuCl4 (1% w/v, 50 mL) was heated to a boil while stirring. Then trisodium citrate (0.75 mL,
1% w/v) was added quickly to the boiling mixture. The solution was refluxed for 15 min, and then
allowed to cool to room temperature. Subsequently, the gold colloid was centrifuged at 13.2 krpm
for 20 min and resuspended in phosphate buffered saline (PBS), pH 7.4. The average diameter of the
AuNPs was determined by UV, TEM, SEM, and DLS.
Two different titanium nanoparticles, TiO2 P25 and TiO2 Hombikat UV100, were purchased
from Evonik (Essen, Germany) and Sachtleben Chemie GmbH (Duisburg, Germany), respectively.
Multiwalled Carbon Nanotubes (CNTs) were purchased from NANOCYL® (NC7000™ series) and
were produced by a Catalytic Chemical Vapor Deposition (CCVD) process. Halloysite nanoclay was
purchased from Sigma Aldrich (Saint Louis, MO, USA). P25 or Hombikat TiO2, AuNPs, and HNTs or
CNTs matrices suspensions were prepared respectively at 1 mg/mL, 0.4 mM, and 0.15 mg/mL in 50%
ethanol, and were vortexed and sonicated before use.
4.3. Sample Characterization
UV-Visible measurements were recorded using a Hitachi UH 5300 Spectrophotometer (Hitachi
High-Technologies Corporation Europe, Maidenhead, UK), equipped with 1.0 cm path length quartz
cells and recorded in a range of 400-700 nm. The morphology and shape of the samples have been
evaluated by means of a Zeiss Evo50 Scanning Electron Microscope (SEM, Zeiss, Germany) with an
accelerating voltage of 20 kV and a magnification of 24000 × TEM analyses were performed on a Jeol
Jem 3010 UHR instrument (JEOL, München, Germany).
Diffuse reflectance spectra (DRS) of the powders were measured on a UV-Vis scanning
spectrophotometer (Perkin-Elmer, Waltham, MA, USA) equipped with a diffuse reflectance accessory.
A “total white” Perkin Elmer reference material was used as a reference.
4.4. Cell Lines and Animal Models
Procedures involving animals and their care were conducted in conformity with the following
laws, regulations, and policies governing the care and use of laboratory animals: Italian Governing Law
(D.lgs 26/2014; Authorization n.19/2008-A issued 6 March 2008 by Ministry of Health); Mario Negri
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Institutional Regulations and Policies providing internal authorization for persons conducting animal
experiments (Quality Management System Certificate—UNI EN ISO 9001:2008—Reg. N. 8576-A);
the NIH Guide for the Care and Use of Laboratory Animals (2011 edition) and EU directives and
guidelines (EEC Council Directive 2010/63/UE) and in line with Guidelines for the welfare and use
of animals in cancer research [45]. The statement of Compliance (Assurance) with the Public Health
Service (PHS) Policy on Human Care and Use of Laboratory Animals has been recently reviewed
(9/9/2014) and will expire on 30 September 2019 (Animal Welfare Assurance #A5023-01).
Animal experiments have been reviewed and approved by the IRFMN Animal Care and Use
Committee (IACUC) that includes members ad hoc for ethical issues. Animals were housed in the
Institute’s Animal Care facilities which meet international standards. They were regularly checked
by a certified veterinarian who is responsible for health monitoring, animal welfare supervision,
experimental protocols, and procedures revision.
Six to seven-week-old female NCr-nu/nu mice (from the Harlan Lab) were inoculated
subcutaneously with 107 A2780 cells or fragments of the rare MPM487 human malignant pleural
mesothelioma (obtained from the Mesothelioma Biobank-Pathology Dept, SS Antonio e Biagio General
Hospital, Alessandria, Italy). Tumor growth was measured with a digital caliper two/three times a
week and the tumor volume (mm3) was calculated as (length (mm) × width2 (mm2))/2.
When tumors reached approximately 500 mg, the animals were treated with different drugs or
with the vehicle as a negative control. Mice bearing xenografts were treated with vehicle (CTRL)
or a single dose of drug (60 mg/kg i.v. for PTX, 400 mg/kg for IMT p.o., 20 mg/kg for LCT p.o.).
Animals were sacrificed 1 hour after treatment (4 h for PTX) under CO2 and all efforts were made to
minimize suffering.
Tumors and organs were explanted, then immediately snap-frozen in liquid nitrogen and stored
at −80 ◦C until analysis.
4.5. Mass Spectrometry
The different nanomaterials tested as matrices were firstly screened by spotting 0.5 µL of
100 pmol/µL drug standard solutions on the MALDI steel plate. After complete drying in air of
the drug standard spots, 0.5 µL of matrix suspensions described above were spotted on top of the
different drugs samples. Matrices were also tested on tissues to evaluate the influence of the biological
matrix on the ion signal intensity, following the MSI protocol we recently published [22]. Briefly,
frozen tissues were cut into 10 µm thick sections using a cryo-microtome (Leica Microsystems, Wetzler,
Germany) at 20 ◦C and mounted on pre-cooled MALDI plates (Opti-TOF 384 Well insert) by standard
thaw-mounting techniques. One section every 300 µm was cut from the central part of the control
and the treated tumors. The plates were then dried overnight in a vacuum drier at room temperature.
Different drug standards were spotted on control tumor sections, then each plate was sprayed with
different matrix suspensions using a BD 180 precision double-action trigger airbrush (Fenga, Mexico)
with a 0.20 mm nozzle diameter, using nitrogen at 0.2 atm. Care was taken to avoid over-spraying the
matrix suspension on a single point so as to avoid the formation of droplets that would wet the surface
with possible damage of the tissue structure, analyte diffusion, or partial detachment of the slice from
the plate.
A MALDI 4800 TOF-TOF (AB SCIEX Old Connecticut Path, Framingham, MA, USA) was used,
equipped with a 355 nm Nd:YAG laser with a 200 Hz repetition rate, controlled by the 4000 Series
Explorer TM software (AB SCIEX Old Connecticut Path, Framingham, MA, USA). MS spectra were
acquired with 20 laser shots with an intensity of 6000 arbitrary units, with a bin size of 1.0 ns, acquiring
spectra in reflectron, both in negative and positive-ion mode. Images of tissue sections were acquired
using the 4800 Imaging Tool Software (www.maldi-msi.org, M. Stoeckli, Novartis Pharma, Basel,
Switzerland) with an imaging raster of 100 µm. Tissue View software 1.1 (AB SCIEX Old Connecticut
Path, Framingham, MA, USA) was used to process and display the ion distributions inside the tumor
sections. The ions plotted for each drug are reported in Appendix A (Figures A1–A6).
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5. Conclusions
Testing different types of materials has made it possible to ionize molecules with different
molecular weights and chemical properties, overcoming the problem of high background noise in the
low mass range that is typical in classic MALDI experiments. Moreover, with these nanomaterials we
could visualize the mitotic inhibitor PTX and the tyrosine kinase inhibitor IMT inside tumors harvested
from treated mice.
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Figure A2. OTX mass spectra examples in (a) reflectron negative ion mode with the relative molecular 
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Figure A3. IMT mass spectra examples in (a) reflectron negative ion mode with the relative molecular 
structure and fragment detected using Halloysite matrix and (b) reflectron positive ion mode using 
gold nanoparticles. 
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Figure A4. LCT mass spectra examples in (a) reflectron negative ion mode with the relative molecular 
structure and fragment detected using halloysite matrix and (b) reflectron positive ion mode using 
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Figure A5. DOXO mass spectra examples in (a) reflectron negative ion mode with the relative 
molecular structure and fragment detected using TiO2 Hombikat nanoparticles and (b) reflectron 
positive ion mode using TiO2 Hombikat nanoparticles. 
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